Skip to main content

10 Result(s)

within Patrick J. Morris Remove this filter

and

  1. No Access

    Article

    The show must go on. Reply to “Distinct functions of S-ketamine and R-ketamine in mediating biobehavioral processes of drug dependency: comments on Bonaventura et al” by Insop Shim

    Jordi Bonaventura, Sherry Lam, Meghan Carlton, Matthew Boehm… in Molecular Psychiatry (2023)

  2. No Access

    Article

    Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search

    The off-label use of racemic ketamine and the FDA approval of (S)-ketamine are promising developments for the treatment of depression. Nevertheless, racemic ketamine and (S)-ketamine are controlled substances ...

    Jordi Bonaventura, Juan L. Gomez, Meghan L. Carlton, Sherry Lam… in Molecular Psychiatry (2022)

  3. Article

    Open Access

    Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration

    Subanesthetic-dose racemic (R,S)-ketamine (ketamine) produces rapid, robust, and sustained antidepressant effects in major depressive disorder (MDD) and bipolar disorder (BD) and has also been shown to effectivel...

    Ruin Moaddel, Panos Zanos, Cristan A. Farmer, Bashkim Kadriu… in Translational Psychiatry (2022)

    Download PDF (1421 KB) View Article

  4. No Access

    Article

    Time will tell. Reply to “Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al.” by Chen et al.

    Jordi Bonaventura, Sherry Lam, Meghan Carlton, Matthew Boehm… in Molecular Psychiatry (2022)

  5. No Access

    Article

    Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability

    Ketamine, a racemic mixture of (S)-ketamine and (R)-ketamine enantiomers, has been used as an anesthetic, analgesic and more recently, as an antidepressant. However, ketamine has known abuse liability (the ten...

    Jordi Bonaventura, Sherry Lam, Meghan Carlton, Matthew A. Boehm… in Molecular Psychiatry (2021)

  6. Article

    Open Access

    High-potency ligands for DREADD imaging and activation in rodents and monkeys

    Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are a popular chemogenetic technology for manipulation of neuronal activity in uninstrumented awake animals with potential for human applica...

    Jordi Bonaventura, Mark A. G. Eldridge, Feng Hu, Juan L. Gomez… in Nature Communications (2019)

    Download PDF (2144 KB) View Article

  7. No Access

    Article

    Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects

    (R,S)-Ketamine produces rapid, robust, and sustained antidepressant effects in major depressive disorder. Specifically, its pharmacological efficacy in treatment refractory depression is considered a major bre...

    Ruin Moaddel, Michelle Shardell, Mohammed Khadeer, Jacqueline Lovett… in Psychopharmacology (2018)

  8. No Access

    Article

    Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma

    The growth of adult and paediatric brain tumours depends on a microenvironmental signalling pathway involving the activity-regulated secretion of neuroligin-3 (NLGN3) from normal neurons and oligodendrocyte pr...

    Humsa S. Venkatesh, Lydia T. Tam, Pamelyn J. Woo, James Lennon, Surya Nagaraja… in Nature (2017)

  9. No Access

    Article

    Zanos et al. reply

    Panos Zanos, Ruin Moaddel, Patrick J. Morris, Polymnia Georgiou… in Nature (2017)

  10. No Access

    Article

    NMDAR inhibition-independent antidepressant actions of ketamine metabolites

    Major depressive disorder affects around 16 per cent of the world population at some point in their lives. Despite the availability of numerous monoaminergic-based antidepressants, most patients require severa...

    Panos Zanos, Ruin Moaddel, Patrick J. Morris, Polymnia Georgiou… in Nature (2016)